Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
about
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncologyTackling ALK in non-small cell lung cancer: the role of novel inhibitorsMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerFibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung CancerGenomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung CancerPatients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor.Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Detection of ALK rearrangements in lung cancer patients using a homebrew PCR assayPerformance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Lung Cancer Biomarkers.Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Lung cancer as a paradigm for precision oncology in solid tumours.ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approachesLiquid biopsy in the practice of neo-oncologyNext-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients.Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung.Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.NSCLC molecular testing in Central and Eastern European countries.
P2860
Q26738387-1D290B19-E029-4A82-9184-DC69CD7386D8Q26740329-D52A75C3-95AE-4644-A804-DE281D71CF24Q26771116-A1C8DAEE-EC28-4817-BA8C-565EB51C9313Q35743009-B2AD8831-97F6-4088-A543-EF6A8E30304FQ35993683-328DAF0A-9E49-493E-8BF2-C700AF0F8E6BQ36462950-FEB60FFF-3E33-4FBA-B219-24F975C1D48FQ37392933-B7FA4913-014D-4359-8560-654E6C12ED5DQ37424085-62A24CF4-4DE7-4B3E-BE3E-00E7DDE456A5Q37665697-12EE9E24-28D7-4918-803F-4297CBA5D48CQ37688499-0633C6D1-E4C7-4350-A208-CBD6E890F567Q37696243-7EB02DCB-2610-4BB2-8AE7-2EADD64E4B77Q37702598-E5A953C0-0D22-453F-998C-DCE7EBA29D28Q38649524-130615D0-45BC-4DF6-A8D0-3C64BED0AFD3Q38651989-4CE5FF6A-A925-40B6-BC2A-9F2AEC77638EQ38663460-336C2252-EA2D-4E37-BCB5-31EE7F8DB0D8Q38816700-0D0317DB-B869-41DB-8CAB-7C37D9074C76Q39027394-744A5172-25A4-453A-BD85-9ADD595BF0C5Q39278116-941720A9-83AC-455E-9BD5-49AB74923FF9Q39449763-4F33AFE4-0FCF-4FFB-B29F-DBD253FDE1F8Q40084048-90C19F96-20E5-486D-947A-FA5A2E9806FBQ40513502-DCEC4D0A-05C2-4D77-A35A-8A42CFEC20B4Q40523842-7CD1934C-94D2-43CB-B39B-D66297A16E5FQ42117389-FBB6218A-2240-4D73-AC8A-AE766ED34F1AQ42286165-7A19CBF2-213B-4A90-953B-B82D032053DAQ42369300-9D9C3D08-6EE6-461F-9A83-276C6C5503DBQ42415357-8B934BF9-D5DB-4D97-ADC5-033E2109CDB7Q47140225-E0C9FCA4-D960-4078-8ED5-67894693E4DAQ47220523-EB3AF5B8-8A08-4702-BD16-AC1C3C9A93EDQ47281800-8857D691-F0C6-4624-8A03-8B9810B65DCCQ47578326-6B77CDF5-8323-47C1-A992-8D0B6E7E8D41Q48108243-AB8448FA-4A72-42A3-AE45-6D2A377ACA52Q48254761-431149DA-0B0D-448A-AE5E-FB173549C581Q52666918-75313D5D-F3BB-4DC9-9D68-5498A8270A4EQ52720230-300EC358-C70A-406D-BBB9-597947D847AAQ52854883-AE9843C2-0EB9-45A2-84D2-2688D0C8F9E8Q54118554-5AB7AE3B-811D-4468-A93A-D8C979A587A4Q54960911-D2CB6305-4C4B-4530-B4ED-9DD30E0D3814Q54983714-61899EE0-D48A-46C4-B493-673E05A11671Q55030710-47C06BFC-E1E5-4736-8395-220CC261235BQ55284375-09204284-D052-4EF1-A846-D9CEF64B2BAB
P2860
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@ast
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@en
type
label
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@ast
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@en
prefLabel
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@ast
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@en
P2093
P2860
P1433
P1476
Fluorescence in situ hybridiza ...... rearrangement in lung cancer.
@en
P2093
Addie Dvir
Doron Lipson
Fred R Hirsch
Gary A Palmer
Lior Soussan-Gutman
Marina Pekar-Zlotin
Maya Ilouze
Murry Wynes
Paul A Bunn
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0389
P577
2015-02-26T00:00:00Z